公开(公告)号：US20170253594A1

公开(公告)日：2017-09-07

申请号：US15600023

申请日：2017-05-19

Applicant: Ariad Pharmaceuticals, Inc.

Inventor： Wei-Sheng Huang ,  Yongjin Gong ,  Feng Li ,  Nicholas E. Bencivenga ,  David C. Delgamo ,  Anna Kohlmann ,  William C. Shakespeare ,  Ranny M. Thomas ,  Xiaotian Zhu ,  Angela V. West ,  Willmen Youngsaye ,  Yun Zhang ,  Tianjun Zhou

IPC: C07D471/04 ,  C07D403/04 ,  C07D401/14 ,  C07D405/12 ,  C07F9/6558

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07F9/65583

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

公开(公告)号：US20190218212A1

公开(公告)日：2019-07-18

申请号：US16257577

申请日：2019-01-25

Applicant: Ariad Pharmaceuticals, Inc.

Inventor： Wei-Sheng Huang ,  Yongjin Gong ,  Feng Li ,  Nicholas E. Bencivenga ,  David C. Dalgarno ,  Anna Kohlmann ,  William C. Shakespeare ,  Ranny M. Thomas ,  Xiaotian Zhu ,  Angela V. West ,  Willmen Youngsaye ,  Yun Zhang ,  Tianjun Zhou

IPC: C07D471/04 ,  C07F9/6558 ,  C07D405/12 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D401/14 ,  C07D401/04

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07F9/65583

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

公开(公告)号：US10227342B2

公开(公告)日：2019-03-12

申请号：US15319637

申请日：2015-05-13

Applicant: ARIAD PHARMACEUTICALS, INC.

Inventor： Wei-Sheng Huang ,  Yongjin Gong ,  Feng Li ,  Nicholas E. Bencivenga ,  David C. Dalgarno ,  Anna Kohlmann ,  William C. Shakespeare ,  Ranny M. Thomas ,  Xiaotian Zhu ,  Angela West ,  Willmen Youngsaye ,  Yun Zhang ,  Tianjun Zhou

IPC: C07D403/14 ,  A61K31/506 ,  C07D471/04 ,  C07D405/12 ,  C07D403/04 ,  C07D401/14 ,  C07F9/6558

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

公开(公告)号：US09796712B2

公开(公告)日：2017-10-24

申请号：US15600023

申请日：2017-05-19

Applicant: Ariad Pharmaceuticals, Inc.

Inventor： Wei-Sheng Huang ,  Yongjin Gong ,  Feng Li ,  Nicholas E. Bencivenga ,  David C. Dalgarno ,  Anna Kohlmann ,  William C. Shakespeare ,  Ranny M. Thomas ,  Xiaotian Zhu ,  Angela V. West ,  Willmen Youngsaye ,  Yun Zhang ,  Tianjun Zhou

IPC: A61K31/506 ,  C07D403/14 ,  C07D471/04 ,  C07D405/12 ,  C07F9/6558 ,  C07D401/14 ,  C07D403/04

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07F9/65583

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.